News
With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback